KR20220054082A - Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it - Google Patents

Abstract

The present invention relates to a method for extracting an extract containing a functional ingredient for preventing obesity from a fruit of Eleutherococcus sessiliflorus. The Eleutherococcus sessiliflorus fruit extract according to the present invention has an excellent inhibitory effect on weight gain and body fat increase due to obesity, so it can be usefully used as a composition for preventing or treating obesity.

Description

An extract containing an obesity prevention functional ingredient and a method for manufacturing the same {Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it}

The present invention relates to a method for extracting an extract containing a functional ingredient for preventing obesity from A. oleifera fruit.

In general, obesity refers to a state in which there is an excess of adipose tissue in the body, and is a phenomenon in which energy consumed from food is not in balance with energy consumed through physical activity, and the surplus energy is accumulated as body fat. If body fat increases abnormally due to energy imbalance over a long period of time, various metabolic diseases and adult diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, etc. are induced, which is emerging as a serious social problem not only in the West but also in Korea. .

Various aspects of research are being conducted worldwide for the development of anti-obesity drugs. Drugs for the treatment of obesity can be broadly divided into fat absorption inhibition, lipolysis and heat generation promotion, appetite and satiety control, protein metabolism inhibition, and emotional regulation related to food intake. Representative anti-obesity treatments include Xenical™, which suppresses fat absorption by using orstat as a raw material, and Reductil™, which suppresses appetite by stimulating the sympathetic nervous system using sibutramine as the main ingredient. . However, in the case of Xenical™, side effects such as fatty stools, abdominal pain, vomiting, itching, and liver damage have been reported. Controversy has arisen over the recent tightening of standards for use.

In addition to drug therapy through these anti-obesity drugs, methods for preventing and treating obesity include diet to limit food intake, exercise therapy to increase energy consumption, and psychotherapy, behavioral therapy, and surgical therapy.

As a preferred treatment method for obesity, it is suggested as the safest and most effective method to promote energy consumption through exercise and to combine drugs for the treatment of obesity with fewer side effects. However, in the case of drugs for the treatment of obesity, serious side effects have been reported as in the examples of Xenical™ and Reductil™ above, and clear trust in safety is not supported. Therefore, there is a demand for the development of a substance that shows excellent anti-obesity efficacy and guarantees safety for the human body.

Accordingly, the present inventors have made an effort to develop a natural material effective for the treatment of obesity without any side effects, and at the end of an effort to develop a natural material effective for the treatment of obesity, the present inventors have found that the extract of the present invention has an anti-obesity or therapeutic effect, and completed a composition for preventing or treating obesity using the same. .

Korean Patent No. 0996577 Korean Patent No. 0588469

It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of obesity, which contains the extract of oleracea as an active ingredient.

It is also another object of the present invention to provide a health functional food composition for preventing or improving obesity, including an extract of oleracea.

In addition, another object of the present invention is to add 50% ethanol to the pulverized sagebrush fruit and extract at 10 to 60 ℃ for 30 minutes to 48 hours; And to provide a method for preparing a composition for preventing or improving obesity, comprising the step of filtration and concentration of the extracted extract after the extraction, followed by freeze-drying.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity, comprising the extract of oleracea as an active ingredient.

In one embodiment of the present invention, the extract can be extracted from the fruit part.

In one embodiment of the present invention, the solvent used for the extraction is methanol, ethanol, acetone, ethyl acetate, hexane, butanol, methylene chloride, water or any one solvent selected from the group consisting of a mixed solvent thereof. can

In one embodiment of the present invention, the extract can be extracted from 50 to 80% ethanol extract at a temperature of 10 to 60 ℃ the extract.

In addition, the present invention provides a health functional food composition for preventing or improving obesity, comprising an extract of oleracea.

In one embodiment of the present invention, the extract can be extracted from the fruit part.

Further, the present invention comprises the steps of adding 50% ethanol to the pulverized sagebrush fruit and extracting at 10 to 60° C. for 30 minutes to 48 hours; And it provides a method for preparing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction, and then freeze-drying.

Since the extract according to the present invention has an excellent inhibitory effect on weight gain and body fat increase due to obesity, it can be usefully used as a composition for preventing or treating obesity.

Figure 1 is the result of confirming the change in body weight by administration of the present invention oleracea fruit extract in an obesity-induced animal model.
Figure 2 is the result of confirming the weight of abdominal fat and epididymal fat by the administration of the extract of the present invention in an obesity-induced animal model.
3 is a result of checking the weight of the liver, spleen, lung and kidney in order to confirm the change in the long-term weight loss caused by the administration of the extract of the oleracea fruit.

Hereinafter, preferred embodiments of the present invention will be described in more detail. However, it should be understood that the present invention may be embodied in many different forms and is not limited to the described embodiments. It should be noted that the embodiments of the present invention described below are intended to sufficiently convey the spirit of the present invention to those skilled in the art.

In addition, terms used in this specification are terms used to properly express preferred embodiments of the present invention, which may vary depending on the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part "includes" a certain element, it means that other elements may be further included, rather than excluding other elements, unless otherwise stated.

The present invention provides a pharmaceutical composition for preventing or treating obesity, comprising an extract of oleracea as an active ingredient.

In the present invention, the extract may be extracted using any one part selected from the stem, fruit, or root of the oleander, but among the above-mentioned parts, the extract extracted from the fruit of the oleander may have a better anti-obesity effect. can

The term "extract" as used in the present invention refers to a preparation obtained by extracting Orchid oleracea with an appropriate extraction solvent and evaporating the solvent, and is not limited thereto, but is not limited thereto, but an extract obtained by extraction treatment, a dilution of the extract, or It may be a dried product obtained by drying a concentrate or an extract, a crude product or a purified product thereof. The extract of S. oleraceae can be prepared using general extraction methods, separation and purification methods known in the art. The extraction method is not limited thereto, but preferably, methods such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction may be used.

The extract according to the present invention may be obtained by extracting and separating from nature using extraction and separation methods known in the art, and the "extract" as defined in the present invention is extracted from A. For example, crude extracts, polar solvent-soluble extracts, or non-polar solvent-soluble extracts are included. As a suitable solvent for extracting the extract from the A. spp., any pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto, for example, purified water, methanol ( methanol), ethanol, propanol, isopropanol, alcohol having 1 to 4 carbon atoms, including butanol, acetone, ether, benzene, chloroform ( Various solvents such as chloroform), ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination, but most preferably ethanol.

As the extraction method, any one of methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method, compression method, etc. may be selected and used, but most preferably, hot water extraction method may be used. .

In addition, the desired extract may be further subjected to a conventional fractionation process, and may be purified using a conventional purification method.

There is no limitation on the method for preparing the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying the primary extract extracted by the hot water extraction or solvent extraction method described above.

As used herein, the term “composition” refers to a mixture in which other chemical components such as diluents or carriers are mixed with the extract of the present invention.

As used herein, the term "carrier (vehicle)" is defined as a compound that facilitates the addition of the compound into a cell or tissue. For example, but not limited to, dimethylsulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into cells or tissues of living organisms.

As used herein, the term “diluent” is defined as a compound that not only stabilizes the biologically active form of the target compound, but is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.

In the present invention, the term "prevention" refers to any action of suppressing or delaying obesity by administration of the pharmaceutical composition according to the present invention.

As used herein, the term “treatment” refers to any action that improves or beneficially changes obesity symptoms by administration of the pharmaceutical composition. Those of ordinary skill in the art to which the present invention pertains, with reference to the data presented by the Korean Medical Association, etc., know the exact standard of the disease for which the composition of the present application is effective, and can determine the degree of improvement, improvement and treatment will be.

Unless otherwise defined, all technical terms used in the present invention have the meanings commonly understood by those skilled in the art in the relevant field of the present invention. In addition, although preferred methods and samples are described herein, similar or equivalent ones are also included in the scope of the present invention.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. The adjuvant may be used without limitation as long as it is known in the art, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase the immunity thereof.

The pharmaceutical composition according to the present invention may be prepared in a form in which the active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injection solutions according to conventional methods, respectively. .

In the case of formulation, it may be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, and surfactant commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin. It can be prepared by mixing and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As a base of the suppository, witepsol, tween 61, cacao butter, laurin, glycerogelatin, etc. can be used.

The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration can be envisaged, for example, by oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated in various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard, soft capsules, solutions, suspensions, emulsifiers, syrups, granules, and the like. crose, mannitol, sorbitol, cellulose and/or glycine), lubricants (eg silica, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol). In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and optionally starch, agar, alginic acid. or a disintegrant such as its sodium salt or a boiling mixture and/or absorbent, coloring, flavoring and sweetening agent. The formulation may be prepared by conventional mixing, granulating or coating methods.

A typical example of a formulation for parenteral administration is an injection formulation, and examples of a solvent for the injection formulation include water, Ringer's solution, isotonic saline, or suspension. The sterile, fixed oil of the injectable preparation can be used as a solvent or suspending medium, and any non-irritating fixed oil including mono- and di-glycerides can be used for this purpose. The injection preparation may use fatty acids such as oleic acid.

Hereinafter, the present invention will be described in detail by way of embodiments of the present invention with reference to the accompanying drawings. However, the following examples are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted, and , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

In addition, the present invention provides a food composition for the prevention or improvement of obesity comprising the extract of oleracea as an active ingredient.

The type of the food composition is not particularly limited as long as it is commonly manufactured and/or sold. For example, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc. It can be used in the form of pills, powders, granules, needles, tablets, capsules or beverages, and includes all health functional foods in the ordinary sense.

The health drink composition is not particularly limited in the liquid component other than containing the extract according to the present invention, and may contain various flavoring agents or natural carbohydrates as an additional component like a conventional beverage.

In general, the amount of the extract of oleracea contained in the health functional food may be included in an amount of 0.1 to 50% by weight, preferably 1 to 40% by weight of the total food weight.

In addition, in the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

Further, the present invention comprises the steps of adding 50% ethanol to the pulverized sagebrush fruit and extracting at 10 to 60° C. for 30 minutes to 48 hours; And it provides a method for preparing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction, and then freeze-drying.

Hereinafter, the present invention will be described in more detail by way of Examples. However, the following examples are only examples for easily explaining the content and scope of the technical idea of the present invention, and thereby the technical scope of the present invention is not limited or changed. In addition, various modifications and changes within the scope of the technical spirit of the present invention based on these examples can be easily determined by those skilled in the art.

Example 1. Preparation of extract from oleracea fruit

1 kg of hot-air-dried oleifera fruit was powdered, mixed with 3L of 50% fermented alcohol, and stirred at room temperature for 24 hours. The above process was repeated twice with 3L of 50% fermented alcohol. After filtration on filter paper and concentration in vacuo, an ethanol extract from A. oleracea was obtained.

Experimental Example 1. Confirmation of the weight loss effect of the fruit extract of oleracea

In order to confirm the weight loss effect of the oleifera fruit extract, an experiment was conducted as follows.

The whole experimental group was treated with guava leaf in the normal group fed with normal feed, the high fat diet group fed with the high fat diet (HFD), the high fat diet group administered with a cucumber extract, and the high fat diet group. The extract was classified into the administered group.

In order to observe the anti-obesity effect, 3 mg/mouse of a cucumber extract at a concentration that did not observe toxicity in the high-fat diet group and 3 mg/mouse of guava leaf extract, a functional raw material for reducing body fat as a control group, were orally administered (p.o).

As a result, as shown in FIG. 1 , the body weight increased by the high fat diet (HFD) was decreased in the experimental group administered with the A. C. C. C. berry extract, and in particular, in the case of the increased body weight until the last day (4 weeks), the C. C. It was confirmed that the group administered with the extract effectively suppressed weight gain, and it was found that the weight loss effect was more excellent when compared to the group administered with the guava leaf extract, the notified raw material.

Experimental Example 2. Confirmation of the weight reduction effect of Abdominal fat and epididymal fat of the fruit extract

In order to observe the anti-obesity effect, the abdominal fat and epididymal fat of the entire experimental group of Experimental Example 1 were excised and the weight change was confirmed by taking advantage of the fact that the body fat weight increased along with the weight increase when obesity was induced by the high-fat diet.

As a result, as shown in FIG. 2, it was observed that the weight of abdominal fat and epididymal fat increased by the high-fat diet was effectively reduced when the Acupunctureus extract was administered, and the fat weight reduction effect was more excellent compared to the group administered with the guava leaf extract. could see that

Experimental Example 3. Measurement of toxic expression level in organs of A. oleracea fruit extract

Four tissues (liver, spleen, lung, and kidney) were excised and the weight change was measured to determine whether organ toxicity due to the administration of the oleracea extract and a high-fat diet.

As a result, as shown in FIG. 3 , it was confirmed that the weights of the liver, spleen, lungs and kidneys did not change significantly before and after administration of the extract, and did not significantly affect the organ weight reduction by administration of the extract. confirmed that.

Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific embodiments described above, and it is common in the technical field to which the present invention pertains without departing from the gist of the present invention as claimed in the claims. Various modifications and improvements are possible by those having the knowledge of, of course, and these modifications and improvements should not be individually understood from the technical spirit or prospect of the present invention.

Claims (7)

A pharmaceutical composition for the prevention or treatment of obesity, comprising the extract of oleracea as an active ingredient. The method of claim 1,
The extract is a pharmaceutical composition for preventing or treating obesity, characterized in that the fruit part is extracted. The method of claim 1,
The solvent used for the extraction is characterized in that the extraction with any one solvent selected from the group consisting of methanol, ethanol, acetone, ethyl acetate, hexane, butanol, methylene chloride, water, or a mixed solvent thereof, obesity prevention or treatment pharmaceutical composition for use. The method of claim 1,
The extract is a pharmaceutical composition for preventing or treating obesity, characterized in that the 50 ~ 80% ethanol extract is extracted at a temperature of 10 ~ 60 ℃. A health functional food composition for the prevention or improvement of obesity, comprising an extract of oleracea. 6. The method of claim 5,
The extract is a health functional food composition for preventing or improving obesity, characterized in that the fruit part is extracted. extracting at 10 to 60° C. for 30 minutes to 48 hours by adding 50% ethanol to the pulverized sagebrush; and
After the extraction, the method for preparing a composition for preventing or improving obesity, comprising the step of filtration and concentration of the extracted extract, followed by freeze-drying.

Images